Physicochemical Properties
| Molecular Formula | C25H26FN3O7 |
| Molecular Weight | 499.49 |
| Appearance | Typically exists as solid at room temperature |
| HS Tariff Code | 2934.99.9001 |
| Storage |
Powder-20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition | Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs) |
Biological Activity
| Targets | Topoisomerase I Topoisomerase II GLUT1 |
| ln Vitro | 3-Fluoro-evodiamine glucose (0-0.5 μM, 12 h) exhibits antiproliferative activity and cytotoxicity in cancer cells U87MG, A549 and HCT116 by inducing reactive oxygen species (ROS) accumulation and DNA damage with an IC50 of 0.064–0.113 μM[1]. 3-Fluoro-evodiamine glucose (0-0.05 μM, 24 h) dose-dependently inhibits the migration and invasion of HCT116 cells[1]. |
| ln Vivo | 3-Fluoro-evodiamine glucose (10 mg/kg, intraperitoneal injection, single dose) showed good pharmacokinetic properties in mice, with a half-life of 2.41 h, a plasma exposure Cmax of 4627 h·ng/mL, an AUC0-t of 4008 h·ng/mL, and an average residence time of 0.802 h[1]. 3-Fluoro-evodiamine glucose (10-20 mg/kg, intraperitoneal injection, twice a day for 21 days) showed antitumor efficacy in HCT116 xenograft nude mice, with a tumor growth inhibition rate TGI of 72%-82% and no obvious toxicity[1]. |
| Cell Assay |
Western Blot Analysis[1] Cell Types: HCT116 Concentration: 0-0.5 μM Incubation Duration: 12 h Experimental Results: Upregulated levels of γ-H2AX and induced DNA damage. Cell Migration Assay [1] Cell Types: HCT116 Concentration: 0-0.05 μM Incubation Duration: 24 h Experimental Results: Repressed the wound heal with the rate of 37%-1.1%. |
| Animal Protocol |
Animal/Disease Models:HCT116 xenograft BALB/c nude mice[1] Doses: 10-20 mg/kg Route of Administration: ip, two injections every days for 21 days Experimental Results: Inhibited tumor growth with TGI of 72-82%, without body weight loss. |
| References |
[1]. Design of Evodiamine-Glucose Conjugates with Improved In Vivo Antitumor Activity. J Med Chem. 2024 May 9;67(9):7373-7384. |
Solubility Data
| Solubility (In Vitro) | May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples |
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples. Injection Formulations (e.g. IP/IV/IM/SC) Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] *Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Injection Formulation 5: 2-Hydroxypropyl-β-cyclodextrin : Saline = 50 : 50 (i.e. 500 μL 2-Hydroxypropyl-β-cyclodextrin → 500 μL Saline) Injection Formulation 6: DMSO : PEG300 : castor oil : Saline = 5 : 10 : 20 : 65 (i.e. 50 μL DMSO → 100 μLPEG300 → 200 μL castor oil → 650 μL Saline) Injection Formulation 7: Ethanol : Cremophor : Saline = 10： 10 : 80 (i.e. 100 μL Ethanol → 100 μL Cremophor → 800 μL Saline) Injection Formulation 8: Dissolve in Cremophor/Ethanol (50 : 50), then diluted by Saline Injection Formulation 9: EtOH : Corn oil = 10 : 90 (i.e. 100 μL EtOH → 900 μL Corn oil) Injection Formulation 10: EtOH : PEG300：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL EtOH → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Oral Formulations Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). Oral Formulation 3: Dissolved in PEG400 Oral Formulation 4: Suspend in 0.2% Carboxymethyl cellulose Oral Formulation 5: Dissolve in 0.25% Tween 80 and 0.5% Carboxymethyl cellulose Oral Formulation 6: Mixing with food powders Note: Please be aware that the above formulations are for reference only. InvivoChem strongly recommends customers to read literature methods/protocols carefully before determining which formulation you should use for in vivo studies, as different compounds have different solubility properties and have to be formulated differently. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0020 mL | 10.0102 mL | 20.0204 mL | |
| 5 mM | 0.4004 mL | 2.0020 mL | 4.0041 mL | |
| 10 mM | 0.2002 mL | 1.0010 mL | 2.0020 mL |